What happened
Yungjin Pharm updated a previously disclosed supply contract with Zhongshan Belling Biotechnology Co., Ltd., now worth US$45.3M, about 27.32% of its recent annual revenue, running through Aug 2036.
For context, this single contract equals about 27.32% of the company's most recent annual revenue.
| Counterparty | Zhongshan Belling Biotechnology Co., Ltd. |
|---|---|
| Contract value | US$45.3M |
| vs. recent revenue | 27.32% |
| Through | Aug 2036 (from Aug 2026) |
| Filed | 2026-08-12, [Amended] Supply contract signed |
| Source | DART rcept 20260812800977 → open original filing |
Source: DART. Information only, not investment advice.